

November 06, 2025

To, Dy. General Manager **Department of Corporate Services,** BSE Ltd., P. J. Towers, Dalal Street, Fort, Mumbai - 400 001

To, The Manager – Listing, National Stock Exchange of India Ltd., Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 543322 **Ref: Scrip Name: ALIVUS** 

Dear Sirs,

# **Sub: Press Release**

Pursuant to regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing herewith the Press Release of the Company for the Second Quarter and Half Year ended September 30, 2025.

You are requested to take the same on record.

Thanking You.

Yours faithfully, For Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited)

**Rudalf Corriea Company Secretary and Compliance Officer** 

Encl.: As above

Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited)





#### PRESS RELEASE

For Immediate dissemination



# Alivus Life Sciences delivers a strong revenue growth of 16% YoY for Q2FY26 EBITDA Margins of 33.0%, up 480 bps YoY

**Mumbai, November 06, 2025: Alivus Life Sciences Limited (***formerly Glenmark Life Sciences Limited***)**, a leading developer and manufacturer of select, high-value, non-commoditized, Active Pharmaceutical Ingredients (APIs) in chronic therapeutic areas, today announced its financial results for the quarter and half year ended September 30, 2025.

For Q2FY26, Alivus registered a Revenue from operations of Rs. 5,880 Mn, a growth of 16.0% YoY. For H1FY26, Revenue from operations was Rs.11,898 Mn, a growth of 8.6% YoY.

For Q2FY26, EBITDA was at Rs. 1,939 Mn, a growth of 35.7% YoY. EBITDA margins were at 33.0%, up 480 bps YoY.

For H1FY26, EBITDA was at Rs. 3,752 Mn, a growth of 21.9% YoY. EBITDA margins were at 31.5%, up 340 bps YoY.

PAT for Q2FY26 stood at Rs. 1,301 Mn, a growth of 36.5% YoY and PAT margins were at 22.1%, up 330 bps YoY.

PAT for H1FY26 stood at Rs. 2,516 Mn, a growth of 21.7% YoY and PAT margins were at 21.1%, up 220 bps YoY.

During H1FY26, the company generated a strong free cash flow of Rs. 1,477 Mn leading to Cash and Cash Equivalents (including short term investments) of Rs. 6,526 Mn as of September 30, 2025.

Commenting on the company's performance Dr. Yasir Rawjee, MD & CEO, Alivus Life Sciences Limited said, "Our performance, this quarter, was fuelled by strong momentum in the non-GPL business, which delivered an impressive 39.7% YoY growth. Non-GPL business has shown a robust performance over last four quarters, driven by healthy demand across key geographies including ROW, LATAM, Japan, Europe, and India, all of which contributed meaningfully to the overall performance.

As we look forward, we remain confident of delivering a stronger performance in second half. This outlook is supported by continued robustness in non-GPL business and a better visibility on GPL business. Moreover, a continued ramp-up of our CDMO projects gives us confidence in the overall growth of our business.


We remain confident of maintaining margins at around 30%, despite the absence of PLI benefits. The margins are reinforced by a robust pipeline of new launches and operational efficiencies."

**Tushar Mistry, CFO, Alivus Life Sciences Limited said,** "At Alivus Life Sciences, we delivered a strong revenue growth of 16% in Q2FY26. During the quarter, gross and EBITDA margins were at 57.7% and 33% respectively, at the upper end of our guided ranges of above 55% and 30%, supported by a favourable product mix, successful new launches, and continued cost efficiency. Notably, we maintained margins beyond our guidance even without the PLI scheme benefits, reflecting the robustness in our operations.

The Company generated strong cash flow from operations of Rs. 148 crores in Q2FY26, with cash & cash equivalents of Rs. 653 crores on the books as of 30th September 2025, providing ample support for our ongoing growth plans and allowing us to sustain a healthy, debt-free balance sheet."

#### PRESS RELEASE

For Immediate dissemination



### **Additional Highlights:**

- DMF / CEP filings continue across major markets, taking the total cumulative filings to 586 as on September 30, 2025
- The HP API portfolio has 26 APIs in the active grid with 10 products validated, seven products in advanced stages of development and nine products under lab development stage.

## **Capex Update:**

Solapur – Phase 1 construction work is in progress for 200 KL capacity

## **About Alivus Life Sciences Ltd (ALIVUS)**

Alivus Life Sciences Limited (Formerly Glenmark Life Sciences Limited) (BSE: 543322, NSE: ALIVUS), is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes. The company is increasingly providing CDMO services to a range of multinational and specialty pharmaceutical companies. It has a diversified portfolio of 170 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan, and the Rest of the World (RoW).

The company's four manufacturing facilities are located in Ankleshwar, Dahej, Mohol and Kurkumbh with a total installed capacity of 1424 KL, which are regularly inspected by global regulators such as USFDA, PMDA (Japan) and EDQM (Europe). Alivus Life Sciences is listed on BSE and NSE.

Learn more about Alivus Life Sciences Limited on https://www.alivus.com

#### For any further queries please contact:

Soumi Rao | General Manager - Corporate Communications

Email: Soumi.Rao@glenmarklifesciences.com

Mobile: 98701 96931

Ernst & Young LLP - Investor Relations

**Diwakar Pingle** 

Email: Diwakar.Pingle@in.ey.com

Runjhun Jain

Email: Runjhun.Jain1@in.ey.com

Sneha Salian

Email: Sneha2.Salian@in.ey.com